Use of a Chagas Urine Nanoparticle Test (Chunap) to Correlate with Parasitemia Levels in T. cruzi/HIV Co-infected Patients

Background Early diagnosis of reactivated Chagas disease in HIV patients could be lifesaving. In Latin America, the diagnosis is made by microscopical detection of the T. cruzi parasite in the blood; a diagnostic test that lacks sensitivity. This study evaluates if levels of T. cruzi antigens in urine, determined by Chunap (Chagas urine nanoparticle test), are correlated with parasitemia levels in T. cruzi/HIV co-infected patients. Methodology/Principal Findings T. cruzi antigens in urine of HIV patients (N = 55: 31 T. cruzi infected and 24 T. cruzi serology negative) were concentrated using hydrogel particles and quantified by Western Blot and a calibration curve. Reactivation of Chagas disease was defined by the observation of parasites in blood by microscopy. Parasitemia levels in patients with serology positive for Chagas disease were classified as follows: High parasitemia or reactivation of Chagas disease (detectable parasitemia by microscopy), moderate parasitemia (undetectable by microscopy but detectable by qPCR), and negative parasitemia (undetectable by microscopy and qPCR). The percentage of positive results detected by Chunap was: 100% (7/7) in cases of reactivation, 91.7% (11/12) in cases of moderate parasitemia, and 41.7% (5/12) in cases of negative parasitemia. Chunap specificity was found to be 91.7%. Linear regression analysis demonstrated a direct relationship between parasitemia levels and urine T. cruzi antigen concentrations (p<0.001). A cut-off of > 105 pg was chosen to determine patients with reactivation of Chagas disease (7/7). Antigenuria levels were 36.08 times (95% CI: 7.28 to 64.88) higher in patients with CD4+ lymphocyte counts below 200/mL (p = 0.016). No significant differences were found in HIV loads and CD8+ lymphocyte counts. Conclusion Chunap shows potential for early detection of Chagas reactivation. With appropriate adaptation, this diagnostic test can be used to monitor Chagas disease status in T. cruzi/HIV co-infected patients.

[1]  E. Kenu,et al.  Diagnostic accuracy of the rapid urine lipoarabinomannan test for pulmonary tuberculosis among HIV-infected adults in Ghana–findings from the DETECT HIV-TB study , 2015, BMC Infectious Diseases.

[2]  L. Liotta,et al.  Use of a Novel Chagas Urine Nanoparticle Test (Chunap) for Diagnosis of Congenital Chagas Disease , 2014, PLoS neglected tropical diseases.

[3]  T. F. Rinke de Wit,et al.  Performance and Logistical Challenges of Alternative HIV-1 Virological Monitoring Options in a Clinical Setting of Harare, Zimbabwe , 2014, BioMed research international.

[4]  V. Fink,et al.  Benznidazole Treatment of Chagasic Encephalitis in Pregnant Woman with AIDS , 2013, Emerging infectious diseases.

[5]  R. Gilman,et al.  Detection of Soluble Antigen and DNA of Trypanosoma cruzi in Urine Is Independent of Renal Injury in the Guinea Pig Model , 2013, PloS one.

[6]  C. Bern.  Chagas disease in the immunosuppressed host , 2012, Current opinion in infectious diseases.

[7]  Weidong Zhou,et al.  Multifunctional Core–Shell Nanoparticles: Discovery of Previously Invisible Biomarkers , 2011, Journal of the American Chemical Society.

[8]  V. L. D. de Freitas,et al.  Real-Time PCR in HIV/Trypanosoma cruzi Coinfection with and without Chagas Disease Reactivation: Association with HIV Viral Load and CD4+ Level , 2011, PLoS neglected tropical diseases.

[9]  M. Ison,et al.  Screening and Treatment of Chagas Disease in Organ Transplant Recipients in the United States: Recommendations from the Chagas in Transplant Working Group , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[10]  E. Petricoin,et al.  The use of hydrogel microparticles to sequester and concentrate bacterial antigens in a urine test for Lyme disease. , 2011, Biomaterials.

[11]  R. Gilman,et al.  Cavia porcellus as a model for experimental infection by Trypanosoma cruzi. , 2010, The American journal of pathology.

[12]  E. Petricoin,et al.  Nanoparticle technology: addressing the fundamental roadblocks to protein biomarker discovery. , 2010, Current molecular medicine.

[13]  R. Gilman,et al.  Congenital Trypanosoma cruzi transmission in Santa Cruz, Bolivia. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  N. M. Matsuda,et al.  The Chronic Gastrointestinal Manifestations of Chagas Disease , 2009, Clinics.

[15]  C. Franco-Paredes,et al.  Chagasic encephalitis in HIV patients: common presentation of an evolving epidemiological and clinical association. , 2009, The Lancet. Infectious diseases.

[16]  Weidong Zhou,et al.  Core-Shell Hydrogel Particles Harvest, Concentrate and Preserve Labile Low Abundance Biomarkers , 2009, PloS one.

[17]  Virginia Espina,et al.  Concentration and preservation of very low abundance biomarkers in urine, such as human growth hormone (hGH), by Cibacron Blue F3G-A loaded hydrogel particles , 2008, Nano research.

[18]  R. Gilman,et al.  Polymerase chain reaction for chronic Trypanosoma cruzi infection yields higher sensitivity in blood clot than buffy coat or whole blood specimens. , 2008, The American journal of tropical medicine and hygiene.

[19]  M. Corti,et al.  Reactivation of Chagas disease with central nervous system involvement in HIV-infected patients in Argentina, 1992-2007. , 2008, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[20]  J. Chippaux,et al.  Epidemiological evaluation of Chagas disease in a rural area of southern Bolivia. , 2008, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[21]  S. Sauleda,et al.  Development of a real-time PCR assay for Trypanosoma cruzi detection in blood samples. , 2007, Acta tropica.

[22]  A. Sartori,et al.  Manifestations of Chagas disease (American trypanosomiasis) in patients with HIV/AIDS , 2007, Annals of tropical medicine and parasitology.

[23]  V. Sreenivas,et al.  CDC staging based on absolute CD4 count and CD4 percentage in an HIV‐1‐infected Indian population: treatment implications , 2005, Clinical and experimental immunology.

[24]  A. F. Ribeiro,et al.  Chagasic meningoencephalitis: case report of a recently included AIDS-defining illness in Brazil. , 2004, Revista do Instituto de Medicina Tropical de Sao Paulo.

[25]  H. Monção,et al.  Reactivation of Chagas' disease leading to the diagnosis of acquired immunodeficiency syndrome , 2002 .

[26]  M. Lopes,et al.  Exacerbation of HIV viral load simultaneous with asymptomatic reactivation of chronic Chagas' disease. , 2002, The American journal of tropical medicine and hygiene.

[27]  J. E. Neto,et al.  Trypanosoma cruzi parasitemia in chronic Chagas disease: comparison between human immunodeficiency virus (HIV)-positive and HIV-negative patients. , 2002, The Journal of infectious diseases.

[28]  A Prata,et al.  Clinical and epidemiological aspects of Chagas disease. , 2001, The Lancet. Infectious diseases.

[29]  A. Rassi,et al.  Chagas' Heart Disease , 2000, Clinical cardiology.

[30]  E. Chapadeiro,et al.  Chagasic meningoencephalitis in the immunodeficient. , 1998, Arquivos de neuro-psiquiatria.

[31]  J. Coura,et al.  Immunoblot assay using excreted-secreted antigens of Trypanosoma cruzi in serodiagnosis of congenital, acute, and chronic Chagas' disease , 1996, Journal of clinical microbiology.

[32]  J. J. Lucas,et al.  Expression of a novel cell surface lipophosphoglycan-like glycoconjugate in Trypanosoma cruzi epimastigotes. , 1994, The Journal of biological chemistry.

[33]  E. Azogue.  Women and congenital Chagas' disease in Santa Cruz, Bolivia: epidemiological and sociocultural aspects. , 1993, Social science & medicine.

[34]  A. Katzin,et al.  Trypanosoma cruzi: detection of a circulating antigen in urine of chagasic patients sharing common epitopes with an immunodominant repetitive antigen. , 1993, Experimental parasitology.

[35]  A. Katzin,et al.  Antigenuria in chronic chagasic patients detected by a monoclonal antibody raised against Trypanosoma cruzi. , 1989, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[36]  S. Cappa,et al.  Direct micromethod for diagnosis of acute and congenital Chagas' disease , 1983, Journal of clinical microbiology.

[37]  Weidong Zhou,et al.  Smart hydrogel particles: biomarker harvesting: one-step affinity purification, size exclusion, and protection against degradation. , 2008, Nano letters.

[38]  H. Rivera,et al.  Prevalence of oral lesions in HIV patients related to CD4 cell count and viral load in a Venezuelan population. , 2006, Medicina oral, patologia oral y cirugia bucal.

[39]  M. Corti,et al.  Prolonged survival and immune reconstitution after chagasic meningoencephalitis in a patient with acquired immunodeficiency syndrome. , 2006, Revista da Sociedade Brasileira de Medicina Tropical.